Haroutioun Shahinian, MD
Hematology & Oncology · El Paso, TXNPI 1639184005
Payments from drug & device makers
Across 305 payments — averaging $2832.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Bioinnovation$222K
- Sanofi US Services Inc.$219K
- Seagen Inc.$185K
- AbbVie$77K
- Pfizer$56K
- Institut DE Recherches Internationales Servier$32K
- plus $73K from 32 others
Across 1 payment — averaging $56,272 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inmune Bio Inc.$56K
What the payments were for
- Consulting fees$4,37040%
- Travel & lodging$1,23311%
- Food & beverage$3,82235%
- Education$3984%
- Other$1,19611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Bioinnovation | 17 | $222,427 |
| Sanofi US Services Inc. | 21 | $219,188 |
| Seagen Inc. | 7 | $184,832 |
| AbbVie | 18 | $76,550 |
| Pfizer | 29 | $55,926 |
| Institut DE Recherches Internationales Servier | 9 | $32,010 |
| Regeneron | 5 | $31,950 |
| Merck | 7 | $30,030 |
| Bayer | 10 | $5,868 |
| Novartis | 48 | $1,699 |
| Institut DE Recherches Servier | 2 | $465 |
| Johnson & Johnson(2 entities) | 19 | $454 |
| E.r. Squibb & Sons, L.L.C. | 29 | $343 |
| Mckesson Specialty Care Distribution, LLC | 4 | $266 |
| Astellas Pharma US Inc | 11 | $265 |
| Genentech USA, Inc. | 13 | $235 |
| Incyte Corporation | 4 | $161 |
| Gilead(2 entities) | 5 | $152 |
| Eisai Inc. | 8 | $140 |
| Ipsen Biopharmaceuticals, Inc | 1 | $124 |
| Amgen | 7 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $85 |
| AstraZeneca | 5 | $82 |
| Medtronic | 1 | $81 |
| Recordati_rare_diseases_inc. | 1 | $80 |
| Exelixis Inc. | 4 | $62 |
| Puma Biotechnology, Inc. | 1 | $60 |
| Tesaro, Inc. | 2 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $40 |
| Shire North American Group Inc | 2 | $36 |
| Bristol Myers Squibb | 2 | $33 |
| Karyopharm Therapeutics Inc. | 2 | $32 |
| Lilly USA, LLC | 2 | $31 |
| EMD Serono, Inc. | 2 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Sanofi | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$863,969 in reported general payments places this provider in the 85th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 93 | $1,524,784 |
| RevlimidLenalidomide | 48 | $1,109,702 |
| Lenalidomide | 59 | $894,159 |
| JakafiRuxolitinib Phosphate | 47 | $857,200 |
| PromactaEltrombopag Olamine | 53 | $810,685 |
| CabometyxCabozantinib S-Malate | 18 | $466,399 |
| TagrissoOsimertinib Mesylate | 22 | $409,382 |
| DopteletAvatrombopag Maleate | 24 | $306,990 |
| SprycelDasatinib | 15 | $277,957 |
| NeulastaPegfilgrastim | 36 | $263,804 |
| IbrancePalbociclib | 13 | $211,923 |
| EliquisApixaban | 241 | $200,535 |
| XtandiEnzalutamide | 11 | $176,200 |
| ProcritEpoetin Alfa | 56 | $164,852 |
| ZarxioFilgrastim-Sndz | 49 | $153,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $40 | $1,524,78493 claims |
| Bristol Myers SquibbRevlimid | $33 | $1,109,70248 claims |
| Incyte CorporationJakafi | $161 | $857,20047 claims |
| NovartisPromacta | $1,699 | $810,68553 claims |
| PfizerIbrance, Eliquis, Nyvepria, Zirabev, Retacrit | $55,926 | $545,812314 claims |
| Exelixis Inc.Cabometyx | $62 | $466,39918 claims |
| AstraZenecaTagrisso | $82 | $409,38222 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Reblozyl | $343 | $381,50027 claims |
| AmgenNeulasta | $123 | $263,80436 claims |
| Johnson & JohnsonProcrit, Xarelto | $454 | $207,41289 claims |
| Astellas Pharma US IncXtandi | $265 | $176,20011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in El Paso
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Drew RascoSan Antonio$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.